Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines

Cancer

Volumn 95, Issue 10, 2002, Pages 2243-2251

  Yoshizawa, Kaname ^a   Cioca, Daniel P ^a   Kawa, Shigeyuki ^a   Tanaka, Eiji ^a   Kiyosawa, Kendo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Caspase; Cell cycle; Hepatocellular carcimona; P21; P27; Peroxisome proliferator activated receptor ; Retinoblastoma protein; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BIOCHEMICAL MARKER; CASPASE 3; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; LIGAND; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLSERINE; PIOGLITAZONE; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; RETINOBLASTOMA PROTEIN; ROSIGLITAZONE; TROGLITAZONE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LIGANDS; LIVER NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0037110628     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10906     Document Type: Article

References (33)

1. Kiyosawa K, Tanaka E, Sodeyama T. Hepatitis C virus and hepatocellular carcinoma. In: Reesink HW. Hepatitis C. Basel: Karge, 1998:161-180.
2. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: The second decade. Cell. 1995;83:835-839.
3. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
4. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature. 1992;358:771-774.
5. Goldstein BJ. Differentiating members of the thiazolidinedione class: A focus on efficacy. Diabetes Metab Res Rev. 2001; 18:S16-22.
6. Sugimura A, Kiriyama Y, Nochi H, et al. Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 1999;261:833-837.
7. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell. 1998; 1:465-470.
8. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806-8811.
9. Kubota T, Koshizuka K, Williamson EA, et al. Ligands for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-3352.
10. Demetri GD, Fletcher CDM, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 1999;96:3951-3956.
11. 12,14 prostaglandin J2. J Biol Chem. 1999; 279:17042-17048.
12. 2 induce apoptosis in normal and malignant B-lineage cells. J Immunol. 2000;165:6941-6948.
13. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 2000; 60:1129-1138.
14. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPABγ. Nat Med. 1998;4:1046-1052.
15. Brockman JA, Gupta RA, DiBois RN. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology. 1998;115: 1049-1055.
16. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999;16:135-139.
17. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kipl in human pancreatic carcinoma cells. Cancer Res. 2000;60:5558-5564.
18. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPABγ ligand troglitazone. Pancreas. 2002;24:1-7.
19. Takahashi T, Fujiwara Y, Higuchi K, et al. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J On-col. 2001;19:465-471.
20. Koga H, Sakisaka S, Harada M, et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087-1097.
21. Rumi MAK, Sato H, Ishihara S, et al. Peroxisome proliferator-activated receptor γ ligand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer. 2001;84: 1640-1647.
22. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med. 1998;4:1058-1061.
23. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCmin/+mice. Nat Med. 1998;4:1053-1057.
24. Duddy SK, Parker RF, Bleavins MR, et al. p53 is not activated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the troglitazone. Toxicol Appl Pharmacol. 1999;156:106-112.
25. Adams JM, Cary S. The Bcl-2 family protein family: Arbiters of cell survival. Science. 1998;281:1322-1326.
26. Yoshizawa K, Kiyosawa K, Usuda S, et al. New hepatocellular carcinoma cell line SUHC-1 established from a patient with hepatitis C virus RNA in serum. Jpn J Cancer Res. 1992;83: 871-877.
27. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181:1661-1672.
28. Zhang C, Ao Z, Seth A, Schlossman SF. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol. 1996;157:3980-3987.
29. Hirase N, Yanase T, Mu Y-M, et al. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemic cell line HL60. Oncology. 1997;57:17-26.
30. Pettitt AR, Cawley JC. Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukemia. Br J Haematol. 2000;109: 800-804.
31. Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med. 1998;129:36-38.
32. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41.
33. Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 1998;21:2140-2143.